Clinical Trials

Papers
(The H4-Index of Clinical Trials is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Rethinking intercurrent events in defining estimands for tuberculosis trials42
Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges33
A review of current practice in the design and analysis of extremely small stepped-wedge cluster randomized trials30
A critique on “A randomized evaluation of on-site monitoring nested in a multinational randomized trial”23
Industry payments and brand-name tyrosine kinase inhibitor use amid generic entry23
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials23
Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial22
Effects of patient-reported outcome assessment order21
What do we do with our under-enrolled single-center COVID-19 clinical trials?21
Random effect misspecification in stepped wedge designs21
Modeling impact of inflation reduction act price negotiations on new drug pipeline considering differential contributions of large and small biopharmaceutical companies19
A Bayesian adaptive design approach for stepped-wedge cluster randomized trials19
Clinical trial site identification practices and the use of electronic health records in feasibility evaluations: An interview study in the Nordic countries18
Characterization of studies considered and required under Medicare’s coverage with evidence development program16
Influential methods reports for group-randomized trials and related designs15
Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials15
Partner engagement for planning and development of non-pharmacological care pathways in the AIM-Back trial15
Importance of patient engagement in the conduct of pragmatic multicenter randomized controlled trials: The ADAPTABLE experience15
0.071527004241943